Document:

EX-10.16.3

 Exhibit 10.16.3 

SECURITY AGREEMENT 
 THIS SECURITY AGREEMENT dated as of December 22, 2008 (“Security Agreement”), is made by
BIOCEPT, INC., a California corporation (“Grantor”), in favor of THE REISS FAMILY GST EXEMPT MARITAL
DEDUCTION TRUST (“Secured Party”). 

RECITALS 
 A. Secured Party has made and has agreed to make certain advances of money and to extend certain financial accommodations to Grantor as evidenced by that certain Secured
Convertible Promissory Note dated December 22, 2008 executed by Grantor in favor of Secured Party and such other Secured Convertible Promissory Notes which may be executed by Grantor in favor of Secured Party after the date hereof
(individually, the “Note” and, collectively, the “Notes”) and that certain Note and Warrant Purchase Agreement dated December 22, 2008, by and between Grantor and Secured Party (the
“Purchase Agreement”), such advances, future advances, and financial accommodations being referred to herein as the “Loans”. 

B. Secured Party is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall have
executed and delivered to Secured Party this Security Agreement. 
 AGREEMENT 

NOW, THEREFORE, in order to induce Secured Party to make the Loans and for
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and intending to be legally bound, Grantor hereby represents, warrants, covenants and agrees as follows: 

1. DEFINED TERMS. When used in this Security Agreement the following terms
shall have the following meanings (such meanings being equally applicable to both the singular and plural forms of the terms defined): 
 “Bankruptcy Code” means Title XI of the United States Code. 
 “Collateral” shall have the meaning assigned to such term in Section 2 of this Security Agreement. 

“Contracts” means all contracts (including any customer, vendor, supplier, service or maintenance
contract), leases, licenses, undertakings, purchase orders, permits, franchise agreements or other agreements (other than any right evidenced by Chattel Paper, Documents or Instruments), whether in written or electronic form, in or under which
Grantor now holds or hereafter acquires any right, title or interest, including, without limitation, with respect to an Account, any agreement relating to the terms of payment or the terms of performance thereof. 

“Copyright License” means any agreement, whether in written or electronic form, in which Grantor now holds or
hereafter acquires any interest, granting any right in or to any Copyright or Copyright registration (whether Grantor is the licensee or the licensor thereunder) 

  
 1. 

 
including, without limitation, licenses pursuant to which Grantor has obtained the exclusive right to use a copyright owned by a third party. 

“Copyrights” means all of the following now owned or hereafter acquired or created (as a work for
hire for the benefit of Grantor) by Grantor or in which Grantor now holds or hereafter acquires or receives any right or interest, in whole or in part: (a) all copyrights, whether registered or unregistered, held pursuant to the laws of the
United States, any State thereof or any other country; (b) registrations, applications, recordings and proceedings in the United States Copyright Office or in any similar office or agency of the United States, any State thereof or any other
country; (c) any continuations, renewals or extensions thereof; (d) any registrations to be issued in any pending applications, and shall include any right or interest in and to work protectable by any of the foregoing which are presently
or in the future owned, created or authorized (as a work for hire for the benefit of Grantor) or acquired by Grantor, in whole or in part; (e) prior versions of works covered by copyright and all works based upon, derived from or incorporating
such works; (f) income, royalties, damages, claims and payments now and hereafter due and/or payable with respect to copyrights, including, without limitation, damages, claims and recoveries for past, present or future infringement;
(g) rights to sue for past, present and future infringements of any copyright; and (h) any other rights corresponding to any of the foregoing rights throughout the world. 

“Event of Default” any “Event of Default” as defined in the Notes. 

“Intellectual Property” means any intellectual property, in any medium, of any kind or
nature whatsoever, now or hereafter owned or acquired or received by Grantor or in which Grantor now holds or hereafter acquires or receives any right or interest, and shall include, in any event, any Copyright, Copyright License, Trademark,
Trademark License, Patent, Patent License, trade secret, customer list, marketing plan, internet domain name (including any right related to the registration thereof), proprietary or confidential information, mask work, source, object or other
programming code, invention (whether or not patented or patentable), technical information, procedure, design, knowledge, know-how, software, data base, data, skill, expertise, recipe, experience, process,
model, drawing, material or record. 
 “License” means any Copyright License, Patent License,
Trademark License or other license of rights or interests, whether in-bound or out-bound, whether in written or electronic form, now or hereafter owned or acquired or received by Grantor or in which Grantor now holds or hereafter acquires or
receives any right or interest, and shall include any renewals or extensions of any of the foregoing thereof. 

“Lien” means any mortgage, lien, deed of trust, charge, pledge, security interest or other encumbrance.

 “Money” means a medium of exchange authorized or adopted by a domestic or foreign
government and includes a monetary unit of account established by an intergovernmental organization or by agreement between two or more nations. 
 “Patent License” means any agreement, whether in written or electronic form, in which Grantor now holds or hereafter acquires any interest, granting any right with respect to any

  
 2. 

 
invention on which a Patent is in existence (whether Grantor is the licensee or the licensor thereunder). 
 “Patents” means all of the following in which Grantor now holds or hereafter acquires any interest: (a) all letters patent of the United States or any other
country, all registrations and recordings thereof and all applications for letters patent of the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark
Office or in any similar office or agency of the United States, any State thereof or any other country; (b)all reissues, divisions, continuations, renewals, continuations-in-part or extensions thereof; (c) all petty patents, divisionals and
patents of addition; (d) all patents to issue in any such applications; (e) income, royalties, damages, claims and payments now and hereafter due and/or payable with respect to patents, including, without limitation, damages, claims and
recoveries for past, present or future infringement; and (f) rights to sue for past, present and future infringements of any patent. 
 “Permitted Lien” means: (a) any Liens existing on the date of this Security Agreement and set forth on Schedule A attached hereto; (b) Liens for taxes, fees, assessments
or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings; (c) Liens (i) upon or in any Equipment acquired or held by Grantor to secure the purchase price of such Equipment
or indebtedness (including capital leases) incurred solely for the purpose of financing the acquisition of such Equipment or (ii) existing on such Equipment at the time of its acquisition, provided that the Lien is confined solely to the
Equipment so acquired, improvements thereon and the Proceeds of such Equipment; (d) leases or subleases and licenses or sublicenses granted to others in the ordinary course of Grantor’s business if such are not otherwise prohibited under
this Security Agreement and do not interfere in any material respect with the business of Grantor; (e) any right, title or interest of a licensor under a license; (f) Liens arising from judgments, decrees or attachments to the extent and
only so long as such judgment, decree or attachment has not caused or resulted in an Event of Default; (g) easements, reservations, rights-of-way, restrictions, minor defects or irregularities in title and other similar Liens affecting real
property not interfering in any material respect with the ordinary conduct of the business of Grantor; (h) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the
importation of goods; (i) Liens arising solely by virtue of any statutory or common law provision relating to banker’s liens, rights of setoff or similar rights and remedies as to deposit accounts or other funds maintained with a creditor
depository institution; (j) Liens in favor of a depository bank or a securities intermediary pursuant to such depository bank’s or securities intermediary’s customary customer account agreement; provided that any such Liens shall at
no time secure any indebtedness or obligations other than customary fees and charges payable to such depository bank or securities intermediary; (k) statutory or common law Liens of landlords and carriers, warehousemen, mechanics, suppliers,
materialmen, repairmen and other similar Liens, arising in the ordinary course of business and securing obligations that are not yet delinquent or are being contested in good faith by appropriate proceedings; (l) Liens incurred or deposits made
to secure the performance of tenders, bids, leases, statutory or regulatory obligations, surety and appeal bonds, government contracts, performance and return-of-money bonds, and other obligations of like nature, in each case, in the ordinary course
of business; (m) Liens incurred or deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance and other types of social security; (n) pledges and deposits securing liability for

  
 3. 

 
reimbursement or indemnification obligations in respect of letters of credit or bank guarantees for the benefit of landlords; and (o) Liens incurred in connection with the extension, renewal
or refinancing of indebtedness secured by Liens permitted under the preceding clauses, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the
indebtedness being extended, renewed or refinanced does not increase. 
 “Secured
Obligations” means (a) the obligation of Grantor to repay Secured Party all of the unpaid principal amount of, and accrued interest on (including any interest that accrues after the commencement of bankruptcy), the Loans, and
(b) the obligation of Grantor to pay any fees, costs and expenses of Secured Party under the Notes, the Purchase Agreement, or this Security Agreement. 
 “Security Agreement” means this Security Agreement and all Schedules hereto, as the same may from time to time be amended, modified, supplemented or restated. 

“Trademark License” means any agreement, whether in written or electronic form, in which Grantor
now holds or hereafter acquires any interest, granting any right in and to any Trademark or Trademark registration (whether Grantor is the licensee or the licensor thereunder). 

“Trademarks” means any of the following in which Grantor now holds or hereafter acquires any
interest: (a) any trademarks, tradenames, corporate names, company names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs
and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof and any applications in connection therewith, including, without limitation, registrations, recordings and applications
in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country (collectively, the “Marks”); (b) any reissues, extensions or renewals thereof;
(c) the goodwill of the business symbolized by or associated with the Marks; (d) income, royalties, damages, claims and payments now and hereafter due and/or payable with respect to the Marks, including, without limitation, damages, claims
and recoveries for past, present or future infringement; and (e) rights to sue for past, present and future infringements of the Marks. 
 “UCC” means the Uniform Commercial Code as the same may from time to time be in effect in the State of California (and each reference in this Security Agreement to an
Article thereof (denoted as a Division of the UCC as adopted and in effect in the State of California) shall refer to that Article (or Division, as applicable) as from time to time in effect, which in the case of Article 9 shall
include and refer to Revised Article 9 from and after the date Revised Article 9 shall become effective in the State of California); provided, however, in the event that, by reason of mandatory provisions of law, any or all of the
attachment, perfection or priority of Secured Party’s security interest in any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of California, the term “UCC” shall mean
the Uniform Commercial Code (including the Articles thereof) as in effect at such time in such other jurisdiction for purposes of the provisions hereof relating to such attachment, perfection or priority and for purposes of definitions related to
such provisions. 

  
 4. 

 In addition, the following terms shall be defined terms having the meaning set forth for
such terms in the UCC: “Account”, “Account Debtor”, “Chattel Paper”, “Commodity Account”, “Deposit Account”, “Documents”, “Equipment”, “Fixtures”, “General
Intangible”, “Goods”, “Instrument”, “Inventory”, “Investment Property”, “Letter-of-Credit Right”, “Money”, “Payment Intangibles”, “Proceeds”, “Promissory
Notes”, “Securities Account”, and “Supporting Obligations”. Each of the foregoing defined terms shall include all of such items now owned, or hereafter acquired, by Grantor. 

2. GRANT OF SECURITY INTEREST. As collateral security for the full,
prompt, complete and final payment and performance when due (whether at stated maturity, by acceleration or otherwise) of all the Secured Obligations and in order to induce Secured Party to cause the Loans to be made, Grantor hereby assigns,
conveys, mortgages, pledges, hypothecates and transfers to Secured Party, and hereby grants to Secured Party, a security interest in all of Grantor’s right, title and interest in, to and under the following, whether now owned or hereafter
acquired (all of which being collectively referred to herein as the “Collateral”): 
 (a) All
Accounts of Grantor; 
 (b) All Chattel Paper of Grantor; 

(c) All Commodity Accounts of Grantor; 
 (d) All Contracts of Grantor; 
 (e) All Deposit Accounts of Grantor;

 (f) All Documents of Grantor; 
 (g) All General Intangibles of Grantor, including, without limitation, Intellectual Property; 
 (h) All Goods of Grantor, including, without limitation, Equipment, Inventory and Fixtures; 
 (i) All Instruments of Grantor, including, without limitation, Promissory Notes; 
 (j) All Investment Property of Grantor; 
 (k) All Letter-of Credit
Rights of Grantor; 
 (l) All Money of Grantor; 
 (m) All Securities Accounts of Grantor; 
 (n) All Supporting
Obligations of Grantor; 
 (o) All property of Grantor held by Secured Party, or any other party for whom Secured Party
is acting as agent, including, without limitation, all property of every-description 

  
 5. 

 
now or hereafter in the possession or custody of or in transit to Secured Party or such other party for any purpose, including, without limitation, safekeeping, collection or pledge, for the
account of Grantor, or as to which Grantor may have any right or power; 
 (p) All other goods and personal property of
Grantor, wherever located, whether tangible or intangible, and whether now owned or hereafter acquired, existing, leased or consigned by or to Grantor; and 
 (q) To the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for and rents, profits and products of each of the foregoing.

 Notwithstanding the foregoing provisions of this Section 2, the grant, assignment and transfer of a security
interest as provided herein shall not extend to, and the term “Collateral” shall not include: (a) “intent-to-use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce,
the recording of a statement of use with the United States Patent and Trademark Office or otherwise or (b) any Account, Chattel Paper, General Intangible or Promissory Note in which Grantor has any right, title or interest if and to the extent
such Account, Chattel Paper, General Intangible or Promissory Note includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Grantor therein would be prohibited and
would, in and of itself, cause or result in a default thereunder enabling another person party to such Account, Chattel Paper, General Intangible or Promissory Note to enforce any remedy with respect thereto; provided that the foregoing
exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such Account, Chattel Paper, General Intangible or Promissory Note or
(ii) such prohibition would be rendered ineffective pursuant to Sections 9-406(d), 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code) or
principles of equity); provided further that immediately upon the ineffectiveness, lapse or termination of any such provision, the Collateral shall include, and Grantor shall be deemed to have granted on the date hereof a security interest
in, all its rights, title and interests in and to such Account, Chattel Paper, General Intangible or Promissory Note as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed
so as to limit, impair or otherwise affect Secured Party’s unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due
under any such Account, Chattel Paper, General Intangible or Promissory Note and in any such monies and other proceeds of such Account, Chattel Paper, General Intangible or Promissory Note. 

3. RIGHTS OF SECURED PARTY; COLLECTION OF
ACCOUNTS. 
 (a) Notwithstanding anything contained in this Security Agreement to the contrary,
Grantor expressly agrees that it shall remain liable under each of its Contracts, Chattel Paper, Documents, Instruments and Licenses to observe and perform all the conditions and obligations to be observed and performed by it thereunder and that it
shall perform all of its duties and obligations thereunder, all in accordance with and pursuant to the terms and provisions of each such Contract, Chattel Paper, Document, Instrument or License. Secured

  
 6. 

 
Party shall not have any obligation or liability under any such Contract, Chattel Paper, Document, Instrument, or License by reason of or arising out of this Security Agreement or the granting to
Secured Party of a lien therein or the receipt by Secured Party of any payment relating to any such Contract, Chattel Paper, Document, Instrument, or License pursuant hereto, nor shall Secured Party be required or obligated in any manner to perform
or fulfill any of the obligations of Grantor under or pursuant to any such Contract, Chattel Paper, Document, Instrument, or License, or to make any payment, or to make any inquiry as to the nature or the sufficiency of any payment received by it or
the sufficiency of any performance by any party under any such Contract, Chattel Paper, Document, Instrument, or License, or to present or file any claim, or to take any action to collect or enforce any performance or the payment of any amounts
which may have been assigned to it or to which it may be entitled at any time or times. 
 (b) Secured Party authorizes
Grantor to collect its Accounts. At the request of Secured Party, Grantor shall deliver all original and other documents evidencing and relating to the performance of labor or service which created such Accounts, including, without limitation, all
original orders, invoices and shipping receipts. 
 (c) Secured Party may at any time, upon the occurrence and during the
continuance of any Event of Default, notify Account Debtors of Grantor, parties to the Contracts of Grantor, and obligors in respect of Instruments of Grantor and obligors in respect of Chattel Paper of Grantor that the Accounts and the right, title
and interest of Grantor in and under such Contracts, Instruments and Chattel Paper have been assigned to Secured Party and that payments shall be made directly to Secured Party. Upon the occurrence and during the continuance of any Event of Default,
upon the request of Secured Party, Grantor shall so notify such Account Debtors, parties to such Contracts, obligors in respect of such Instruments and obligors in respect of such Chattel Paper. Secured Party may, in its name or in the name of
others, communicate with such Account Debtors, parties to such Contracts, obligors in respect of such Instruments and obligors in respect of such Chattel Paper to verify with such parties, to Secured Party’s satisfaction, the existence, amount
and terms of any such Accounts, Contracts, Instruments or Chattel Paper. 
 4. REPRESENTATIONS
AND WARRANTIES. Grantor hereby represents and warrants to Secured Party that: 
 (a)
Except for the security interest granted to Secured Party under this Security Agreement and Permitted Liens, Grantor is the sole legal and equitable owner of each item of the Collateral in which it purports to grant a security interest hereunder.

 (b) No effective security agreement, financing statement, equivalent security or lien instrument or continuation
statement covering all or any part of the Collateral exists, except such as may have been filed by Grantor in favor of Secured Party pursuant to this Security Agreement and except for Permitted Liens. 

(c) This Security Agreement creates a legal and valid security interest on and in all of the Collateral in which Grantor now has
rights. 

  
 7. 

 (d) Grantor’s taxpayer identification number is set forth in the signature page
hereof. Grantor’s chief executive office, principal place of business, and the place where Grantor maintains its records concerning the Collateral are presently located at the address set forth on the signature page hereof. The Collateral
consisting of goods, other than motor vehicles and such other mobile goods, is presently located at such address and at such additional addresses set forth on Schedule B attached hereto. 

(e) All Collateral of Grantor consisting of Chattel Paper, Instruments or Investment Property is set forth on Schedule C
attached hereto. 
 (f) The name and address of each depository institution at which Grantor maintains any Deposit
Account and the account number and account name of each such Deposit Account is listed on Schedule D attached hereto. The name and address of each securities intermediary or commodity intermediary at which Grantor maintains any Securities
Account or Commodity Account and the account number and account name is listed on Schedule D attached hereto. Grantor agrees to amend Schedule D upon Secured Party’s request to reflect the opening of any additional Deposit
Account, Securities Account or Commodity Account, or closing or changing the account name or number on any existing Deposit Account, Securities Account, or Commodity Account. 
 (g) All Intellectual Property now owned or held by the Grantor are listed on Schedule E attached hereto. 
 5. COVENANTS. Unless Secured Party otherwise consents (which consent shall not be unreasonably withheld), Grantor covenants and agrees with Secured Party that from and after the date
of this Security Agreement and until the Secured Obligations have been performed and paid in full (other than inchoate indemnity obligations) and any commitment of Secured Party to make Loans to Grantor has expired or terminated: 

5.1 Disposition of Collateral. Grantor shall not sell, lease, transfer or otherwise dispose of any of the Collateral (each, a
“Transfer”), or attempt or contract to do so, other than (a) the sale of Inventory in the ordinary course of business, (b) the granting of Licenses in the ordinary course of business and (c) the disposal of
worn-out or obsolete Equipment. 
 5.2 Change of Jurisdiction of Organization, Relocation of Business. Grantor shall not
change its jurisdiction of organization or relocate its chief executive office, principal place of business or its records from such address(es) provided to Secured Party pursuant to Section 4(d) above without at least seven
(7) days prior notice to Secured Party. 
 5.3 Limitation on Liens on Collateral. Grantor shall not, directly or
indirectly, create, permit or suffer to exist, and shall defend the Collateral against and take such other action as is necessary to remove, any Lien on the Collateral, except (a) Permitted Liens and (b) the Lien granted to Secured Party
under this Security Agreement. 

  
 8. 

 5.4 Insurance. Grantor shall maintain insurance policies insuring the Collateral
against loss or damage from such risks and in such amounts and forms and with such companies as are customarily maintained by businesses similar to Grantor. 
 5.5 Taxes, Assessments, Etc. Grantor shall pay promptly when due all property and other taxes, assessments and government charges or levies imposed upon, and all claims (including claims for labor,
materials and supplies) against, the Goods, except to the extent the validity or amount thereof is being contested in good faith and adequate reserves are being maintained in connection therewith. 

5.6 Defense of Intellectual Property. Grantor shall use commercially reasonable efforts to (i) protect, defend and maintain
the validity and enforceability of all Copyrights, Patents and Trademarks material to Grantor’s business and (ii) detect infringements of all Copyrights, Patents and Trademarks material to Grantor’s business. 

5.7 Further Assurances. At any time and from time to time, upon the written request of Secured Party, and at the sole expense of
Grantor, Grantor shall promptly and duly execute and deliver any and all such further instruments and documents and take such further action as Secured Party may reasonably deem necessary or desirable to obtain the full benefits of this Security
Agreement, including, without limitation, (a) executing, delivering and causing to be filed any financing or continuation statements (including “in lieu” continuation statements) under the UCC with respect to the security interests
granted hereby, (b) at Secured Party’s reasonable request, filing or cooperating with Secured Party in filing any forms or other documents required to be recorded with the United States Patent and Trademark Office, United States Copyright
Office, (c) at Secured Party’s reasonable request, placing the interest of Secured Party as lienholder on the certificate of title (or similar evidence of ownership) of any vehicle, watercraft or other Equipment constituting Collateral
owned by Grantor which is covered by a certificate of title (or similar evidence of ownership), (d) executing and delivering and using commercially reasonable efforts to cause the applicable depository institution, securities intermediary,
commodity intermediary or issuer or nominated party under a letter of credit to execute and deliver a collateral control agreement with respect to any Deposit Account, Securities Account or Commodity Account or Letter-of-Credit Right in or to which
Grantor has any right or interest and (e) at Secured Party’s reasonable request, using commercially reasonable efforts to obtain acknowledgments from bailees having possession of any Collateral and waivers of liens from landlords and
mortgagees of any location where any of the Collateral may from time to time be stored or located. Grantor also hereby authorizes Secured Party to file any such financing or continuation statement (including “in lieu” continuation
statements) without the signature of Grantor. 
 6. SECURED PARTY’S
APPOINTMENT AS ATTORNEY-IN-FACT; PERFORMANCE BY SECURED PARTY. 

(a) Subject to Section 6(b) below, Grantor hereby irrevocably constitutes and appoints Secured Party, and any officer
or agent of Secured Party, with full power of substitution, as its true and lawful attorney-in-fact with full, irrevocable power and authority in the place and stead of Grantor and in the name of Grantor or in its own name, from time to time at
Secured Party’s discretion, for the purpose of carrying out the terms of this Security 

  
 9. 

 
Agreement, to take any and all appropriate action and to execute and deliver any and all documents and instruments which may be necessary or desirable to accomplish the purposes of this Security
Agreement and, without limiting the generality of the foregoing, hereby gives Secured Party the power and right, on behalf of Grantor, without notice to or assent by Grantor to do the following: 

(i) to ask, demand, collect, receive and give acquittances and receipts for any and all monies due or to become due under any
Collateral and, in the name of Grantor, in its own name or otherwise to take possession of, endorse and collect any checks, drafts, notes, acceptances or other Instruments for the payment of monies due under any Collateral and to file any claim or
take or commence any other action or proceeding in any court of law or equity or otherwise deemed appropriate by Secured Party for the purpose of collecting any and all such monies due under any Collateral whenever payable; 

(ii) to pay or discharge any Liens, including, without limitation, any tax lien, levied or placed on or threatened against the
Collateral, to effect any repairs or any insurance called for by the terms of this Security Agreement and to pay all or any part of the premiums therefor and the costs thereof, which actions shall be for the benefit of Secured Party and not Grantor;

 (iii) to (1) direct any person liable for any payment under or in respect of any of the Collateral to make
payment of any and all monies due or to become due thereunder directly to Secured Party or as Secured Party shall direct, (2) receive payment of any and all monies, claims and other amounts due or to become due at any time arising out of or in
respect of any Collateral, (3) sign and endorse any invoices, freight or express bills, bills of lading, storage or warehouse receipts, drafts against debtors, assignments, verifications and notices in connection with Accounts and other
Instruments and Documents constituting or relating to the Collateral, (4) commence and prosecute any suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect the Collateral or any part thereof and to
enforce any other right in respect of any Collateral, (5) defend any suit, action or proceeding brought against Grantor with respect to any Collateral, (6) settle, compromise or adjust any suit, action or proceeding described above, and in
connection therewith, give such discharges or releases as Secured Party may deem appropriate, (7) license, or, to the extent permitted by an applicable License, sublicense, whether general, special or otherwise, and whether on an exclusive or
non-exclusive basis, any Copyright, Patent or Trademark throughout the world for such term or terms, on such conditions and in such manner as Secured Party shall in its discretion determine and (8) sell, transfer, pledge, make any agreement
with respect to or otherwise deal with any of the Collateral as fully and completely as though Secured Party were the absolute owner thereof for all purposes; and 
 (iv) to do, at Secured Party’s option and Grantor’s expense, at any time, or from time to time, all acts and things which Secured Party may reasonably deem necessary to protect, preserve
or realize upon the Collateral and Secured Party’s security interest therein in order to effect the intent of this Security Agreement, all as fully and effectively as Grantor might do. 

  
 10.

 (b) Secured Party agrees that, except upon the occurrence and during the continuation
of an Event of Default, it shall not exercise the power of attorney or any rights granted to Secured Party pursuant to this Section 6. Grantor hereby ratifies, to the extent permitted by law, all that said attorney shall lawfully do or
cause to be done by virtue hereof. The power of attorney granted pursuant to this Section 6 is a power coupled with an interest and shall be irrevocable until the Secured Obligations are completely and indefeasibly paid and performed in
full and Secured Party no longer has any commitment to make any Loans to Grantor. 
 (c) If Grantor fails to perform or
comply with any of its agreements contained herein and Secured Party, as provided for by the terms of this Security Agreement, shall perform or comply, or otherwise cause performance or compliance, with such agreement, the reasonable expenses,
including reasonable attorneys’ fees and costs, of Secured Party together with interest thereon at a rate of interest equal to the highest per annum rate of interest charged on the Loans, incurred in connection with such performance or
compliance, shall be payable by Grantor to Secured Party within five (5) business days of demand and shall constitute Secured Obligations secured hereby. 
 7. RIGHTS AND REMEDIES UPON DEFAULT. Beginning on the date which is ten (10) business days after any Event of Default
shall have occurred and while such Event of Default is continuing: 
 (a) Secured Party may exercise in addition to all
other rights and remedies granted to it under this Security Agreement, the Notes, or the Purchase Agreement, all rights and remedies of a secured party under the UCC. Without limiting the generality of the foregoing, Grantor expressly agrees that in
any such event Secured Party, without demand of performance or other demand, advertisement or notice of any kind (except the notice specified below of time and place of public or private sale) to or upon Grantor or any other person, may
(i) reclaim, take possession, recover, store, maintain, finish, repair, prepare for sale or lease, shop, advertise for sale or lease and sell or lease (in the manner provided herein) the Collateral, and in connection with the liquidation of the
Collateral and collection of the accounts receivable pledged as Collateral, use any Trademark, Copyright, or process used or owned by Grantor and (ii) forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof,
and may forthwith sell, lease, assign, give an option or options to purchase or sell or otherwise dispose of and deliver said Collateral (or contract to do so), or any part thereof, in one or more parcels at public or private sale or sales, at any
exchange or broker’s board or at any of Secured Party’s offices or elsewhere at such prices as it may deem commercially reasonable, for cash or on credit or for future delivery without assumption of any credit risk. Grantor further agrees,
at Secured Party’s request, to assemble the Collateral and make it available to the Secured Party at places which Secured Party shall reasonably select, whether at Grantor’s premises or elsewhere. Secured Party shall apply the net proceeds
of any such collection, recovery, receipt, appropriation, realization or sale as provided in Section 7(e), below, with Grantor remaining liable for any deficiency remaining unpaid after such application. Grantor agrees that Secured Party
need not give more than twenty (20) days’ notice of the time and place of any public sale or of the time after which a private sale may take place and that such notice is reasonable notification of such matters. 

  
 11.

 (b) As to any Collateral constituting certificated securities or uncertificated
securities, if, at any time when Secured Party shall determine to exercise its right to sell the whole or any part of such Collateral hereunder, such Collateral or the part thereof to be sold shall not, for any reason whatsoever, be effectively
registered under Securities Act of 1933, as amended (as so amended the “Act”), Secured Party may, in its discretion (subject only to applicable requirements of law), sell such Collateral or part thereof by private sale in
such manner and under such circumstances as Secured Party may deem necessary or advisable, but subject to the other requirements of this Section 7(b), and shall not be required to effect such registration or cause the same to be
effected. Without limiting the generality of the foregoing, in any such event Secured Party may, in its sole discretion, (i) in accordance with applicable securities laws, proceed to make such private sale notwithstanding that a registration
statement for the purpose of registering such Collateral or part thereof could be or shall have been filed under the Act; (ii) approach and negotiate with a single possible purchaser to effect such sale; and (iii) restrict such sale
to a purchaser who will represent and agree that such purchaser is purchasing for its own account, for investment, and not with a view to the distribution or sale of such Collateral or part thereof. In addition to a private sale as
provided above in this Section 7(b), if any of such Collateral shall not be freely distributable to the public without registration under the Act at the time of any proposed sale hereunder, then Secured Party shall not be required to
effect such registration or cause the same to be effected but may, in its sole discretion (subject only to applicable requirements of law), require that any sale hereunder (including a sale at auction) be conducted subject to such restrictions
as Secured Party may, in its sole discretion, deem necessary or appropriate in order that such sale (notwithstanding any failure so to register) may be effected in compliance with the Bankruptcy Code and other laws affecting the enforcement of
creditors’ rights and the Act and all applicable state securities laws. 
 (c) Grantor also agrees to pay all fees,
costs and expenses of Secured Party, including, without limitation, attorneys’ fees, incurred in connection with the enforcement of any of its rights and remedies hereunder. 

(d) Grantor hereby waives presentment, demand, protest or any notice (to the maximum extent permitted by applicable law) of any
kind in connection with this Security Agreement or any Collateral. 
 (e) The Proceeds of any sale, disposition or other
realization upon all or any part of the Collateral shall be distributed by Secured Party in the following order of priorities: 

FIRST, to Secured Party in an amount sufficient to pay in full the costs of Secured Party in
connection with such sale, disposition or other realization, including all fees, costs, expenses, liabilities and advances incurred or made by Secured Party in connection therewith, including, without limitation, attorneys’ fees; 

SECOND, to Secured Party in an amount equal to the then unpaid Secured Obligations; and 

FINALLY, upon payment in full of the Secured Obligations, to Grantor or its representatives, in
accordance with the UCC or as a court of competent jurisdiction may direct. 

  
 12.

 8. INDEMNITY. Grantor agrees to defend, indemnify and hold harmless
Secured Party and its officers, employees, and agents against (a) all obligations, demands, claims, and liabilities claimed or asserted by any other party in connection with the transactions contemplated by this Security Agreement and
(b) all losses or expenses in any way suffered, incurred, or paid by Secured Party as a result of or in any way arising out of, following or consequential to transactions between Secured Party and Grantor, whether under this Security Agreement
or otherwise (including without limitation, reasonable attorneys fees and expenses), except for losses arising from or out of Secured Party’s gross negligence or willful misconduct. 

9. REINSTATEMENT. This Security Agreement shall remain in full force and effect and continue to be effective should
any petition be filed by or against Grantor for liquidation or reorganization, should Grantor become insolvent or make an assignment for the benefit of creditors or should a receiver or trustee be appointed for all or any significant part of
Grantor’s property and assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Secured Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced
in amount, or must otherwise be restored or returned by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment or performance had not been
made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Secured Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

 10. MISCELLANEOUS. 
 10.1 Waivers; Amendments. Any amendment of the Notes, the Purchase Agreement or this Security Agreement shall require the written consent of the Grantor and the Secured Party. 

10.2 Termination of this Security Agreement. Subject to Section 9 hereof, this Security Agreement shall terminate upon
the payment and performance in full of the Secured Obligations. 
 10.3 Successor and Assigns. This Security Agreement
and all obligations of Grantor hereunder shall be binding upon the successors and assigns of Grantor, and shall, together with the rights and remedies of Secured Party hereunder, inure to the benefit of Secured Party, any future holder of any of the
Secured Obligations and their respective successors and assigns. No sales of participations, other sales, assignments, transfers or other dispositions of any agreement governing or instrument evidencing the Secured Obligations or any portion thereof
or interest therein shall in any manner affect the lien granted to Secured Party hereunder. 
 10.4 Governing Law. In all
respects, including all matters of construction, validity and performance, this Security Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California applicable to contracts made and performed in
such state, without regard to the principles thereof regarding conflict of laws, except to the extent that the UCC provides for the application of the law of a different jurisdiction. 

  
 13.

 IN WITNESS WHEREOF, each of the parties
hereto has caused this Security Agreement to be executed and delivered by its duly authorized officer on the date first set forth above. 
  

							
	 ADDRESS OF GRANTOR
	 		 	BIOCEPT, INC., as Grantor
				
	 	 		 	By:	 	/s/ Stephen M. Coutts

							
	 	 		 	Printed Name:	 	Stephen M. Coutts

							
	 	 		 	Title:	 	President & CEO
			
	TAXPAYER IDENTIFICATION NUMBER OF GRANTOR	 		 	JURISDICTION OF ORGANIZATION OF GRANTOR
			
	 	 		 	California

  

			
	 ACCEPTED AND ACKNOWLEDGED BY:

 
 THE REISS FAMILY GST
EXEMPT MARITAL DEDUCTION TRUST, as Secured Party

		
	 By:
	 	/s/ Claire Reiss

			
	 Printed Name:
	 	Claire Reiss

			
	 Title:
	 	Trustee

  

[SIGNATURE PAGE TO SECURITY AGREEMENT] 

 SCHEDULE A 

LIENS EXISTING ON THE DATE OF THIS SECURITY AGREEMENT 
 None 

 SCHEDULE B 

LOCATION OF GOODS 
  

			
	 ENTITY
	  	 ADDRESS

	 Biocept, Inc.
	  	5810 Nancy Ridge Dr., San Diego, CA 92121

 SCHEDULE C 

LIST OF CHATTEL PAPER, INSTRUMENTS, AND 
 INVESTMENT PROPERTY 
 (CERTIFICATED SECURITIES) 

None 

 SCHEDULE D 

DEPOSIT ACCOUNTS, SECURITIES ACCOUNTS AND 
 COMMODITY ACCOUNTS 
 (Including Type of Account, Account Name, Account Number and Name and
Address of Institution/Intermediary) 
  

							
	Description	 	Type of Account	 	Account Name	 	Account Number
				
	 California Coast Credit Union
	 	Savings	 	Biocept Inc.	 	7100001171
	 Address:
	 	California Coast Credit Union, PO Box 502080, San Diego, CA 92150-2080
				
	 SVB General Account
	 	Analysis Checking	 	Biocept Inc.	 	3300575742
	 Address:
	 	Silicon Valley Bank, 3003 Tasman Drive, Santa Clara, CA 95054
				
	 Merrill Lynch Checking
	 	WCMA	 	Biocept Inc.	 	778-07010
	 Address:
	 	Merrill Lynch, 150 Fayetteville Street, Suite 2000, Raleigh, NC 27601-2919
				
	 Merrill Lynch Investment
	 	WCMA/MLPA	 	Biocept Inc.	 	778-07007
	 Address:
	 	Merrill Lynch, 150 Fayetteville Street, Suite 2000, Raleigh, NC 27601-2919
				
	 Ulster Bank Account
	 	Corporate Checking	 	Biocept Europe	 	35180007
	 Address:
	 	Ulster Bank, Donegal County Business Centre, 2nd Floor, 12-14 Main Street
		 	Letterkenny, Co Donegal, Ireland	 	

 SCHEDULE E 

INTELLECTUAL PROPERTY 

Issued/Granted Patents: 
  

																			
	 Attorney
Docket #
	  	 Outside
Counsel
	  	 Title
	  	 Inventor(s)
	  	Product	  	Country	 	Assign. Date/
Reel/Frame	  	Date Filed/
Serial #	  	Pub. Date/
Pub. #	  	Date Issued/
Patent #
	 62685
	  	Fitch, Even, Tabin & Flannery	  	Method of Using an Improved Peptide Nucleic Acid Universal Library to Optimize DNA Sequence Hybridization	  	 S. Hahn
 A. Patron
 R. Fagnani
	  	PNA	  	Europe
(PCT)	 	N/A	  	01/07/1999
 99933646.4
	  	5/2/2001
 EP1095054
	  	10/25/2006

EP 1,095,054 B1

	  	  	  	  	  	Korea
 (PCT)
	 	N/A	  	01/07/1999
 7000159
	  	—	  	3/7/2007
 694914

	 62829
	  	Fitch, Even, Tabin & Flannery	  	Method of Making Biochips and the Biochips Resulting Therefrom	  	S. Hahn	  	Hydroarray	  	US	 	7/19/1999

010110/0277
	  	04/26/1999

09/299,831
	  	N/A	  	01/16/2001

6,174,683

	 66152
	  	Fitch, Even, Tabin & Flannery	  	Peptide Nucleic Acid Precursors and Methods of Preparing Same (CIP-abandoned)	  	 A. Patron
 A. Pervin
	  	PNA	  	US	 	1/5/2000

010523/0685
	  	01/05/2000

09/479,320
	  	N/A	  	08/13/2002

6,433,134

	 66233
	  	Fitch, Even, Tabin & Flannery	  	Method of Making Biochips and The Biochips Resulting Therefrom	  	 R. Fagnani
 S. Hahn
 P. Tsinberg
	  	Hydroarray	  	Europe
(PCT)	 	N/A	  	04/26/2000
 00928450.6
	  	1/23/2002
 EP1173620
	  	11/8/2006
 EP 1,173,620
B1

	  	  	  	  	  	Germany	 	N/A	  	11/8/2006

600 31 772.2-08
	  	N/A	  	9/6/2007

DE 600 31 772 T2

	  	  	  	  	  	Korea
(PCT)	 	N/A	  	04/26/2001
 7013634/2001
	  	—	  	4/13/2007
 709795

	 69905
	  	Fitch, Even, Tabin & Flannery	  	Three Dimensional Format Biochips	  	 R. Fagnani
 S. Hahn
 X. Dong

T. Pircher

S. Matsumoto

P. Tsinberg
	  	Hydroarray	  	Australia
(PCT)	 	N/A	  	10/26/2001
 2002246918
	  	N/A	  	1/11/2007
 AU
2002246918
B2

	  	  	  	  	  	Europe
(PCT)	 	N/A	  	10/26/2001
 01994529.4
	  	7/23/2003
 EP1328810
	  	Published
 No
further
submissions

  
 1 

																			
	 Attorney
Docket #
	  	 Outside
Counsel
	  	 Title
	  	 Inventor(s)
	  	Product	  	Country	 	Assign. Date/
Reel/Frame	  	Date Filed/
Serial #	  	Pub. Date/
Pub. #	  	Date Issued/
Patent #
	 71716
	  	Fitch, Even, Tabin & Flannery	  	Microwell Biochip	  	 P. Tsinberg
 P. Roycroft
 Y. Gerassi

S. Hahn
	  	Microwell	  	Europe
(PCT)	 	N/A	  	10/15/2002

2772545.0-2204
	  	8/11/2004
 EP 1,444,500
	  	6/11/08
 1,444,500

	  	  	  	  	  	Japan
(PCT)	 	N/A	  	10/15/2002
 2003-536,713
	  	3/3/2005
 2005-506,530
	  	Published
 No
further
submissions

	 72711
	  	Fitch, Even, Tabin & Flannery	  	Methods and Gel Compositions for Encapsulating Living Cells and Organic Molecules	  	 S. Hahn
 R. Fagnani
 X. Dong

C. Edman
 P.
Tsinberg
	  	Hydrogel	  	US	 	8/7/2003

013857/0723
	  	04/02/2003

10/398,725
	  	2/12/2004

2004/0029241
	  	02/6/2007

7,172,866

	  	  	  	  	  	Europe
 (PCT)
	 	N/A	  	04/02/2002

02763911.1-2405
	  	1/2/2004
 EP1373472
	  	6/27/2007

1,373,472 – Filed
in GE, FR, GB

	  	  	  	  	  	Germany	 	N/A	  	6/27/2007
 602 20 893.9-08
	  	N/A	  	3/6/2008
 DE60220893T2

	 81633
	  	Fitch, Even, Tabin & Flannery	  	Microarray Hybridization Device Having Bubble-Fracturing Elements	  	 S. Hahn
 J. Steadman
 P. Tsinberg

T. Watanaskul

Y. Gerassi
	  	Hybridization
Device	  	US	 	11/24/2003

014756/0001
	  	11/24/2003

10/722,290
	  	05/26/2005

2005/0112589
	  	07/3/2007

7,238,521

	  	  	  	  	  	Europe
(PCT)	 	N/A	  	11/03/2004
 04800599.5
	  	8/9/2006
 EP1687080
	  	6/24/08
 1,687,080

	 81634
	  	Fitch, Even, Tabin & Flannery	  	Reflective Substrate and Algorithms for 3D Biochip	  	D. Rachlin	  	Substrate	  	US	 	11/4/2004

015338/0315
	  	09/16/2003

10/664,248
	  	Filed w/Non-
Publication
Notice	  	04/3/2007

7,198,901

	 81674
	  	Fitch, Even, Tabin & Flannery	  	Alleviation of Non-Specific Binding in Microarray Assays	  	 Y. Gerassi
 P. Tsinberg
	  	Protein	  	US	 	11/3/2004

015332/0733
	  	8/19/2004

10/922,387
	  	2/23/2006

2006/0040407
	  	08/21/07

7,258,990

	  	  	  	  	  	Europe
(PCT)	 	N/A	  	2/21/2007
 05,808,506.9
	  	5/23/2007
 1,787,120
	  	Abandoned
	 81721
	  	Fitch, Even, Tabin & Flannery	  	 Microwell Biochip
 (Cont.
71716)
	  	 Y. Gerassi
 S. Hahn
 P. Roycroft

P. Tsinberg
	  	Microwell	  	US	 	10/14/2004

015248/0196
	  	04/12/2004

10/823,021
	  	9/30/2004

2004/0191891
	  	05/15/2007

7,217,520

	 81736
	  	Fitch, Even Tabin & Flannery	  	mRNA Expression Analysis	  	T. Pircher	  	Expression
Analysis	  	Europe
(PCT)	 	N/A	  	6/18/2004
 04776771.0-2405
	  	4/26/06
 EP1649060
	  	Abandoned

  
 2 

 Pending Applications: 

 

																			
	 Attorney
Docket #
	  	 Outside
Counsel
	  	 Title
	  	 Inventor(s)
	  	 Product
	  	Country	 	Assign. Date/
Reel/Frame	  	Date Filed/
Serial #	  	Pub. Date/
Pub. #	  	Date Issued/
Patent #
	 62685
	  	Fitch, Even, Tabin & Flannery	  	Method of Using an Improved Peptide Nucleic Acid Universal Library to Optimize DNA Sequence Hybridization	  	 S. Hahn
 A. Patron
 R. Fagnani
	  	PNA	  	WO
(PCT)	 	N/A	  	01/07/1999
 PCT/US99/14969
	  	01/20/2000
 WO0002899
	  	N/A
	  	  	  	  	  	Japan
 (PCT)
	 	N/A	  	01/07/1999
 2000-559,128
	  	7/9/2002
 2002-520,008
	  	Published
	 66233
	  	Fitch, Even, Tabin & Flannery	  	Method of Making Biochips and The Biochips Resulting Therefrom	  	 R. Fagnani
 S. Hahn
 P. Tsinberg
	  	Hydroarray	  	WO
 (PCT)
	 	N/A	  	04/26/2000
 PCT/US001/11282
	  	11/02/2000
 WO/0065097
	  	N/A
	  	  	  	  	  	Japan
 (PCT)
	 	N/A	  	4/26/2000
 2000-614,431
	  	/2002
 2002-543,398
	  	Published
	 69905
	  	Fitch, Even, Tabin & Flannery	  	Three Dimensional Format Biochips	  	 R. Fagnani
 S. Hahn
 X. Dong

T. Pircher

S. Matsumoto

P. Tsinberg
	  	Hydroarray	  	WO
(PCT)	 	N/A	  	10/26/2001
 PCT/US01/51265
	  	8/1/2002
 WO02059372
	  	N/A
	  	  	  	  	  	China
 (PCT)
	 	N/A	  	10/26/2001	  	01 994 529.4	  	Published
	  	  	  	  	  	Japan
 (PCT)
	 	N/A	  	10/26/2001
 2002-559,854
	  	6/17/2004
 2004-518,138
	  	
	  	  	  	  	  	Korea
 (PCT)
	 	N/A	  	10/26/2001
 7008285/2002
	  	Pending	  	
	 71716
	  	Fitch, Even, Tabin & Flannery	  	Microwell Biochip	  	 P. Tsinberg
 P. Roycroft
 Y. Gerassi

S. Hahn
	  	Microwell	  	WO
(PCT)	 	N/A	  	10/15/2001
 PCT/US02/32751
	  	04/24/2003
 WO2003034026
	  	N/A
	 71726
	  	Fitch, Even, Tabin & Flannery	  	Three-Dimensional Format Biochips (CIP)	  	 R. Fagnani
 S. Hahn
 X. Dong

T. Pircher
 S.
Matsumoto
 P. Tsinberg
	  	Hydroarray	  	US	 	5/28/2002

012736/0060
	  	10/25/2001

10/054,728
	  	2/17/2005

2005/0037343
	  	Published
 No
Further
Submissions

  
 3 

																			
	 Attorney
Docket #
	  	 Outside
Counsel
	  	 Title
	  	 Inventor(s)
	  	 Product
	  	Country	 	Assign. Date/
Reel/Frame	  	Date Filed/
Serial #	  	Pub. Date/
Pub. #	  	Date Issued/
Patent #
	 72711
	  	Fitch, Even, Tabin & Flannery	  	Methods and Gel Compositions for Encapsulating Living Cells and Organic Molecules	  	 S. Hahn
 R. Fagnani
 X. Dong

C. Edman
 P.
Tsinberg
	  	Hydrogel	  	WO
(PCT)	 	N/A	  	04/02/2002
 PCT/US02/10411
	  	10/17/2002
 WO2002/081662
	  	N/A
	  	  	  	  	  	Canada
 (PCT)
	 	N/A	  	04/02/2002
 2,443,060
	  	Published	  	Maintain –
no further
submissions
	  	  	  	  	  	Israel
 (PCT)
	 	N/A	  	04/02/2002
 158128
	  	—	  	N/A
	  	  	  	  	  	Japan
 (PCT)
	 	N/A	  	04/02/2002
 2002-580,026
	  	11/4/2004
 2004-533,500
	  	N/A
	 81633
	  	Fitch, Even, Tabin & Flannery	  	Microarray Hybridization Device	  	 S. Hahn
 J. Steadman
 P. Tsinberg

T. Watanaskul

Y. Gerassi
	  	Hybridization Device	  	WO	 	N/A	  	11/03/2004
 PCT/US04/036475
	  	6/16/2005
 WO2005/053827
	  	N/A
	  	  	  	  	  	China
(PCT)	 	N/A	  	5/22/2006
 200480034517.7
	  	12/20/2006
 CN1882382A
	  	Abandoned
	  	  	  	  	  	Hong
Kong	 	N/A	  	6/5/2007
 07105921.6
	  	9/28/2007
 1100820
	  	Abandoned
	  	  	  	  	  	India
(PCT)	 	N/A	  	09/21/2006
 2316/CHENP/2006
	  		  	Abandoned
	  	  	  	  	  	Japan
(PCT)	 	N/A	  	11/7/2006
 2006-541216
	  	6/14/2007
 2007-515627
	  	Abandoned
	  	  	  	  	  	Korea
(PCT)	 	N/A	  	6/22/2006
 7012472/2006
	  	Pending	  	Abandoned

  
 4 

																			
	 Attorney
Docket #
	  	 Outside
Counsel
	  	 Title
	  	 Inventor(s)
	  	 Product
	  	Country	 	Assign. Date/
Reel/Frame	  	Date Filed/
Serial #	  	Pub. Date/
Pub. #	  	Date Issued/
Patent #
	 81665
	  	Fitch, Even, Tabin & Flannery	  	Detection of Chromosomal Disorders	  	 S. Hahn
 Z. Xie
 T. Watanaskul
	  	Chromosomal Disorder Detection	  	US	 	10/4/2004

015217/0311
	  	05/05/2004

10/840,208
	  	11/10/2005

2005/0250111
	  	No Further
Submissions
	  	  	  	  	  	WO	 	N/A	  	04/18/2005
 PCT/US2005/013070
	  	11/24/2005
 WO2005/111237
	  	N/A
	  	  	  	  	  	China
(PCT)	 	N/A	  	12/21/06
 200580020530.1
	  	6/13/2007
 CN1981052A
	  	—
	  	  	  	  	  	Hong
Kong	 	N/A	  	11/6/07
 07112041.7
	  	3/14/08
 1,106,553
	  	—
	  	  	  	  	  	Europe
(PCT)	 	N/A	  	12/4/2006
 05740274.4
	  	3/7/2007
 EP1759011
	  	—
	  	  	  	  	  	India
(PCT)	 	N/A	  	4473/CHENP/2006	  	Pending	  	—
	  	  	  	  	  	Japan
(PCT)	 	N/A	  	11/6/2006
 2007-511389
	  	12/13/2007
 2007-535928
	  	—
	  	  	  	  	  	Korea
(PCT)	 	N/A	  	12/1/2006
 7025434/2006
	  	Pending	  	—
	 81671
	  	Fitch, Even, Tabin & Flannery	  	Detection of STRP Such as Fragile X Syndrome	  	S. Hahn	  	Chromosomal Disorder Detection	  	US	 	4/21/2004

014538/0289
	  	03/01/2004

10/791,209
	  	9/1/2005

2005/0191636
	  	Abandoned
	  	  	  	  	  	WO	 	N/A	  	02/28/2005
 PCT/US05/007049
	  	09/15/2005
 WO2005/085476
	  	N/A
	  	  	  	  	  	China
(PCT)	 	N/A	  	08/31/2006
 200580006466.1
	  	03/23/2007
 CN1926247A
	  	—
	  	  	  	  	  	Hong
Kong	 	N/A	  	6/26/2007
 07106812.6
	  	11/2/2007
 1,102,059
	  	—
	  	  	  	  	  	Europe
(PCT)	 	N/A	  	09/21/2006
 05,724,566.4
	  	11/22/2006
 EP1723261
	  	—
	  	  	  	  	  	India
(PCT)	 	N/A	  	2/28/2005
 3600/CHENP/2006
	  	Pending	  	—
	  	  	  	  	  	Japan
(PCT)	 	N/A	  	01/16/2007
 501418993
	  	9/13/2007
 2007-525998
	  	—
	  	  	  	  	  	Korea
(PCT)	 	N/A	  	10/2/2006
 7020635/2006
	  	Pending	  	—

  
 5 

																			
	 Attorney
Docket #
	  	 Outside
Counsel
	  	 Title
	  	 Inventor(s)
	  	 Product
	  	Country	 	Assign. Date/
Reel/Frame	  	Date Filed/
Serial #	  	Pub. Date/
Pub. #	  	Date Issued/
Patent #
	 81672
	  	Fitch, Even, Tabin & Flannery	  	Protein Microarrays	  	P. Tsinberg	  	Protein	  	US	 	11/18/2004

015391/0794
	  	8/17/2004

10/921,073
	  	2/23/06

2003/0040377
	  	N/A
	  	  	  	  	  	WO	 	N/A	  	8/9/2005
 PCT/US2005/028225
	  	3/2/2006
 WO2006/023324
	  	N/A
	  	  	  	  	  	China
(PCT)	 	N/A	  	2/12/2007
 200580027771.9
	  	Pending	  	No further
submissions
	  	  	  	  	  	Hong
Kong	 	N/A	  	3/26/2008
 08103346.7
	  	Pending	  	No further
submissions
	  	  	  	  	  	Europe
(PCT)	 	N/A	  	2/21/2007
 05,784,703.0
	  	5/2/2007
 1,779,114
	  	No further
submissions
	  	  	  	  	  	India
(PCT)	 	N/A	  	8/9/2005
 1108/CHENP/2007
	  	Pending	  	No further
submissions
	  	  	  	  	  	Japan
(PCT)	 	N/A	  	4/19/2007
 2007-527867
	  	4/3/08
 2008-510165
	  	No further
submissions
	  	  	  	  	  	Korea
(PCT)	 	N/A	  	3/15/2007
 7006000/2007
	  	—	  	No further
submissions
	 81673
	  	Fitch, Even, Tabin & Flannery	  	Microarrays Utilizing Hydrogels	  	P. Tsinberg	  	Hydrogel	  	US	 	10/18/2004

0152561/0623
	  	8/19/2004

10/922,391
	  	2/23/06

2006/0040274
	  	No further
submissions
	  	  	  	  	  	WO	 	N/A	  	8/9/2005
 PCT/US2005/028224
	  	3/2/06
 WO2006/023323
	  	N/A
	  	  	  	  	  	China
(PCT)	 	N/A	  	2/25/2007
 200580028415.9
	  	9/26/07
 CN101044401A
	  	No further
submissions
	  	  	  	  	  	Hong
Kong	 	N/A	  	3/26/2008
 08103349.4
	  	Pending	  	No further
submissions
	  	  	  	  	  	Europe
(PCT)	 	N/A	  	2/21/2007
 05,784,526.5
	  	5/2/2007
 1,779,113
	  	No further
submissions
	  	  	  	  	  	India
(PCT)	 	N/A	  	10/2007
 1144/CHENP/2007
	  	Pending	  	No further
submissions
	  	  	  	  	  	Japan
(PCT)	 	N/A	  	2/19/2007
 2007-527866
	  	4/3/08
 2008-510164
	  	No further
submissions
	  	  	  	  	  	Korea
(PCT)	 	N/A	  	3/15/2007
 7006001/2007
	  	Pending	  	No further
submissions

  
 6 

																			
	 Attorney
Docket #
	  	 Outside
Counsel
	  	 Title
	  	 Inventor(s)
	  	 Product
	  	Country	 	Assign. Date/
Reel/Frame	  	Date Filed/
Serial #	  	Pub. Date/
Pub. #	  	Date Issued/
Patent #
	 81674
	  	Fitch, Even, Tabin & Flannery	  	Alleviation of Non-Specific Binding in Microarray Assays	  	 Y. Gerassi
 P. Tsinberg
	  	Protein	  	WO	 	N/A	  	8/11/2005
 PCT/US2005/028690
	  	3/2/2006
 WO2006/023383
	  	N/A
	  	  	  	  	  	China
(PCT)	 	N/A	  	2/25/2007
 200580028345.7
	  	8/29/2007
 CN101027559A
	  	Abandoned
	  	  	  	  	  	Hong
Kong	 	N/A	  	11/23/2007
 07112786.6
	  	4/3/2008
 1,107,400
	  	Abandoned
	  	  	  	  	  	India
(PCT)	 	N/A	  	10/2007
 1142/CHENP/2007
	  	Pending	  	Abandoned
	  	  	  	  	  	Japan
(PCT)	 	N/A	  	2/19/2007
 2007-527889
	  	4/3/08
 2008-510167
	  	Abandoned
	  	  	  	  	  	Korea
(PCT)	 	N/A	  	3/16/2007
 7006187/2007
	  	Pending	  	Abandoned
	 81736
	  	Fitch, Even, Tabin & Flannery	  	mRNA Expression Analysis	  	T. Pircher	  	Expression Analysis	  	WO	 	N/A	  	06/21/2004
 PCT/US04/019559
	  	01/06/2005
 WO2005/001139
	  	N/A
	  	  	  	  	  	Japan
(PCT)	 	N/A	  	12/27/2005
 2006-517413
	  	11/29/2007
 2007-534298
	  	Abandoned
	 81835
	  	Fitch, Even, Tabin & Flannery	  	3D Format Biochips and Method of Use (CIP 71726)	  	T. Pircher	  	Cell Separation	  	US	 	2/4/2005

015660/0316
	  	12/16/2004

11/015,459
	  	05/12/2005

2005/0100951
	  	N/A
	 86357
	  	Fitch, Even, Tabin & Flannery	  	Methods and Gel Compositions for Encapsulating Living Cells and Organic Molecules (DIV of 72711)	  	 S. Hahn
 R. Fagnani
 X. Dong

C. Edman
 P.
Tsinberg
	  	Hydrogel	  	US	 	N/A	  	02/01/2007

11/670,061
	  	6/21/2007

2007/0141164
	  	Response to
Office Action
Filed
	 BIOE-001/

00US
	  	Cooley, Godward, Kronish	  	Recovery of Rare Cells Using a Microchannel Apparatus with Patterned Posts (Foreign see 86213)	  	 Z. Tang
 R. Bhatt
 P. Tsinberg
	  	MEMs Channel	  	US	 	3/11/2005

015884/0336
	  	1/18/2005

11/038,920
	  	7/20/2006

2006/0160243
	  	Response to
Office Action
filed

  
 7 

																			
	 Attorney
Docket #
	  	 Outside
Counsel
	  	 Title
	  	 Inventor(s)
	  	 Product
	  	Country	 	Assign. Date/
Reel/Frame	  	Date Filed/
Serial #	  	Pub. Date/
Pub. #	  	Date Issued/
Patent #
	 BIOE-001/

01US
	  	Cooley, Godward, Kronish	  	Detection or Isolation of Target Molecules Using a Microchannel Apparatus (CONT. 81816)	  	 Z. Tang
 R. Bhatt
 P. Tsinberg
	  	MEMs Channel	  	US	 	N/A	  	7/19/2006

11/458,668
	  	11/9/2006

2006/0252087
	  	Response to
Office Action
filed
	 BIOE-001/

01WO
	  	  	  	  	  	WO	 	N/A	  	7/18/2007
 PCT/US07/073817
	  	01/24/2008
 WO2008/011486
	  	N/A
	 BIOE-001/

03US
	  	Cooley, Godward, Kronish	  	Cell Separation Using Microchannel Having Patterned Posts (Incorps. 81816 & BIOE-001/02US)	  	 P. Tsinberg
 Z. Tang
 R. Bhatt
	  	MEMs Channel	  	US
(PCT)	 	Pending	  	7/18/2007

11/814,276
	  	Pending	  	Pending Exam
Requested
	 BIOE-001/

03WO
	  	  	  	  	  	WO	 	N/A	  	1/5/2006
 PCT/US2006/000383
	  	07/27/2006
 WO2006/078470
	  	N/A
	 BIOE-001/

03CN
	  	  	  	  	  	China
(PCT)	 	N/A	  	1/5/2006
 200680002401.4
	  	1/9/2008
 CN101102847A
	  	—
	 BIOE-001/

003EP
	  	  	  	  	  	Europe
(PCT)	 	N/A	  	5/31/2007
 06717562.0
	  	Pending	  	—
	 BIOE-001/

03IN
	  	  	  	  	  	India
(PCT)	 	N/A	  	8/14/2007
 2991/KOLNP/2007
	  	Pending	  	—
	 BIOE-001/

03IL
	  	  	  	  	  	Israel
(PCT)	 	N/A	  	Preparing to File	  	—	  	—
	 BIOE-001/

03JP
	  	  	  	  	  	Japan
(PCT)	 	N/A	  	Preparing to File	  	—	  	—
	 BIOE-001/

03KR
	  	  	  	  	  	Korea
(PCT)	 	N/A	  	Preparing to File	  	—	  	—
	 BIOE-001/

03TW
	  	  	  	  	  	Taiwan	 	N/A	  	5/2/2006
 95115566
	  	11/16/2007
 200742612
	  	Request for Exam.
Due 5/2/09

  
 8 

																			
	 Attorney
Docket #
	  	 Outside
Counsel
	  	 Title
	  	 Inventor(s)
	  	 Product
	  	Country	 	Assign. Date/
Reel/Frame	  	Date Filed/
Serial #	  	Pub. Date/
Pub. #	  	Date Issued/
Patent #
	 BIOE-002/

00WO
	  	Cooley, Godward, Kronish	  	Isolation of Cells or the Like from Bodily Fluids (Beads)	  	 R. Bhatt
 P. Tsinberg
	  	Cell Separation	  	WO	 	N/A	  	12/21/2005
 PCT/US2005/046961
	  	7/6/2006
 WO2006/071824
	  	N/A – No
National
Filing
	 BIOE-002/

00US
	  	Cooley, Godward, Kronish	  	Isolation of Cells or the Like from Bodily Fluids (Beads)	  	 R. Bhatt
 P. Tsinberg
	  	Cell Separation	  	US	 	3/4/2005

015838/0143
	  	12/23/2004

11/021,304
	  	6/29/2006

2006/0141045
	  	Issue Fee
Paid
Awaiting
Published

	 BIOE-003/

00US
	  	Cooley, Godward, Kronish	  	Trophoblast Preservation/ Pretreatment Medium and Method	  	T. Pircher	  	Transport Medium	  	US	 	4/24/2006

017518/0416
	  	3/22/2006

11/277,218
	  	9/27/2007

2007/0224588
	  	Abandoned
	 BIOE-004/

00US
	  	Cooley, Godward, Kronish	  	Isolating Fetal Trophoblasts (Mucus Dissolution)	  	 T. Pircher
 R. Fagnani
	  	Cell Separation	  	US	 	5/1/2006

017556/0667
	  	3/23/2006

11/277,288
	  	9/27/2007

2007/0224597
	  	Abandoned
	 BIOE-004/

01WO
	  	  	  	  	  	WO	 	N/A	  	3/22/2007
 PCT/US2007/64705
	  	10/4/2007
 WO2007/112281
	  	N/A
	 BIOE-005/

00US
	  	Cooley, Godward, Kronish	  	Device for Cell Separation and Analysis and Method of Using (covered)	  	 P. Tsinberg
 Z. Tang
	  	MEMs Channel	  	US	 	2/6/2006

017238/0401
	  	01/12/2006

11/331,988
	  	7/12/2007

2007/0161051
	  	Pending
Published
	 BIOE-005/

01WO
	  	  	  	  	  	WO	 	N/A	  	1/12/2007
 PCT/US2007/060518
	  	1/19/2007
 WO2007/082302
	  	N/A
	 BIOE-005/

01CN
	  	  	  	  	  	China
(PCT)	 	—	  	Preparing to File	  	—	  	—
	 BIOE-005/

01EP
	  	  	  	  	  	Europe
(PCT)	 	—	  	Preparing to File	  	—	  	—
	 BIOE-005/

01JP
	  	  	  	  	  	Japan
(PCT)	 	—	  	Preparing to File	  	—	  	—
	 BIOE-005/

01IN
	  	  	  	  	  	India
(PCT)	 	—	  	Preparing to File	  	—	  	—
	 BIOE-005/

01KR
	  	  	  	  	  	Korea
(PCT)	 	—	  	Preparing to File	  	—	  	—
	 BIOE-006/

00US
	  	Cooley, Godward, Kronish	  	Enrichment of Circulating Fetal DNA (BAYLOR)	  	F. Bischoff	  	Cell Separation	  	US	 	8/23/2007

019739/0966
	  	4/11/2007

11/734,224
	  	10/18/2007

2007/0243549
	  	Abandoned
	 BIOE-006/

01WO
	  	  	  	  	  	WO	 	N/A	  	4/11/2007
 PCT/US2007/66475
	  	10/25/2007
 WO2007/121276
	  	N/A

  
 9 

																			
	 Attorney
Docket #
	  	 Outside
Counsel
	  	 Title
	  	 Inventor(s)
	  	 Product
	  	Country	 	Assign. Date/
Reel/Frame	  	Date Filed/
Serial #	  	Pub. Date/
Pub. #	  	Date Issued/
Patent #
	 BIOE-006/

01CN
	  		  		  		  		  	China
(PCT)	 	—	  	—	  	—	  	—
	 BIOE-006/

01EP
	  	  	  	  	  	Europe
(PCT)	 	—	  	—	  	—	  	—
	 BIOE-006/

01JP
	  	  	  	  	  	Japan
(PCT)	 	—	  	—	  	—	  	—
	 BIOE-006/

01IN
	  	  	  	  	  	India
(PCT)	 	—	  	—	  	—	  	—
	 BIOE-006/

01KR
	  	  	  	  	  	Korea
(PCT)	 	—	  	—	  	—	  	—
	 BIOE-007/

00US
	  	Cooley, Godward, Kronish	  	Identification and Isolation of Fetal Cells and Nucleic Acid (PROVISIONAL)	  	F. Bischoff	  	Cell Separation	  	US	 	—	  	9/21/2007

60/974,392
	  	N/A	  	Application Filed
	 BIOE-009/

00US
	  	Cooley, Godward, Kronish	  	Non-Invasive Prenatal Genetic Screen	  	 R. Bhatt
 W. Fan
 R. Tim

F. Bischoff
	  	Cell Separation	  	US	 	020377/0504	  	12/7/2007

11/952,459
	  	Converted
to PCT
and US	  	Application Filed
 National
Phase
Due 6/7/2009

	 BIOE-009/

01WO
	  	  	  	  	  	WO	 	—	  	12/7/2007
 PCT/US2007/86862
	  	—	  	N/A
	 BIOE-010/

01US
	  	Cooley, Godward, Kronish	  	Non-Invasive Detection of Endometrial Cancer (Priority date of 5/2/07)	  	 H. Radisch
 Q. Le
	  	Cell Separation	  	US	 	Pending	  	05/02/2008

12/114,584
	  	—	  	Application Filed

Abandoned

	  	  	  	  	  	WO	 	—	  	5/1/2008
 PCT/US2008/062286
	  	—	  	N/A
	 BIOE-013/

00US
	  	Cooley Godward Kronish	  	 In-Situ Hybridization to Detect RNA and DNA Markers
 (PROVISIONAL)
	  	 R. Bhatt
 W. Fan
 R. Tim
	  	Cell Separation	  	US	 	01/04/2008

020319/0009
	  	8/3/2007

60/953,812
	  	N/A	  	National Phase
Due 2/3/2010
	 BIOE-014/

00US
	  	Cooley Godward Kronish	  	Non-Invasive Isolation of Fetal Nucleic Acid (Partial Lysis) (PROVISIONAL)	  	 R. Bhatt
 K. Kosco
 I. Postor

W. Fan
	  	Cell Separation	  	US	 	—	  	11/1/2007

60/984,698
	  	N/A	  	Application Filed

  
 10 

																			
	 Attorney
Docket #
	  	 Outside
Counsel
	  	 Title
	  	 Inventor(s)
	  	 Product
	  	Country	  	Assign. Date/
Reel/Frame	  	Date Filed/
Serial #	  	Pub. Date/
Pub. #	  	Date Issued/
Patent #
	 BIOE-0015/

00US
	  	Cooley Godward Kronish	  	 Method for Isolating Cell Free Apoptotic or Fetal Nucleic Acids
 (PROVISIONAL)
	  	 R. Bhatt
 W. Fan
	  	Cell Separation	  	US	  	6/9/2008

021068/0429
	  	2/12/2008

61/028,064
	  	N/A	  	Application Filed
	 BIOE-0016/

00US
	  	Cooley Godward Kronish	  	 Device Utilizing Electric Field and Size Cut-Off for the Separation of Changed Species (Electrophoresis)

(PROVISIONAL)
	  	Z. Tang	  	Cell Separation	  	US	  	5/19/2008

020968/0447
	  	4/7/2008

61/043,028
	  	N/A	  	Application Filed

Abandoned

	 BIOE-018/

00US
	  	Cooley Godward Kronish	  	Two-Stage Enrichment of Cell Free Fetal DNA in Maternal Plasma (PROVISIONAL)	  	F. Bischoff	  	Cell Separation	  	US	  	—	  	1/30/2008

61/024,872
	  	N/A	  	Application Filed

  
 11 

 Pending Drafts: 
  

													
	 Attorney
 Docket #
	  	 Outside

Counsel
	  	 Title
	  	 Inventor(s)
	  	Product	  	Country	  	Status
	 BIOE-012/

00US
	  	Cooley Godward Kronish	  	Collection, Separation, Purification and Testing of Trophoblasts	  	T. Pircher	  	Cell Separation	  	US	  	Abandoned
	 BIOE-011/

00US
	  	Cooley Godward Kronish	  	Method and Kit for Cell Separation (Double-Sided Slide)	  	R. Bhatt	  	Cell Separation	  	US	  	Abandon

  
 12 

 TRADEMARKS 
 Registered: 
  

											
	 Outside Counsel
	  	Mark	  	Int’l Class(es)	  	Registry	  	Date Filed/
Serial #	  	Date Registered/
Registration
#
	 US

	 Cooley Godward Kronish LLP
	  	Biocept®	  	9	  	Principal	  	03/22/2002
 78/116,876
	  	08/31/2004
 2,880,222

	 Cooley Godward Kronish LLP
	  	Biocept Laboratories®	  	9/42	  	Principal	  	05/04/2004
 78/412,723
	  	10/17/2006
 3,159,956

	 Cooley Godward Kronish LLP
	  	CEE®	  	44	  	Principal	  	06/10/2005
 78/648,645
	  	10/30/2007
 3,326,287

	 Cooley Godward Kronish LLP
	  	ChipCalc®	  	9	  	Principal	  	12/15/2003
 78/341,146
	  	09/20/2005
 2,999,101

	 Cooley Godward Kronish LLP
	  	HydroArray®	  	1/9	  	Principal	  	08/01/2003
 78/282,032
	  	03/22/2005
 2,934,749

	 Cooley Godward Kronish LLP
	  	3D HydroArray®	  	1/9	  	Principal	  	09/12/2003
 78/299,957
	  	09/27/2005
 3,000,775

	 Cooley Godward Kronish LLP
	  	Engineering new directions
in diagnosticsTM	  	42/44	  	Principal	  	5/27/2008	  	07/01/08
 3,458,860

	European Community (CTM)
	 Cooley Godward Kronish LLP
	  	preCEEd®	  	9/42	  	N/A	  	11/16/2005
 4724101
	  	11/16/2006
 4724101

	Japan
	 Cooley Godward Kronish LLP
	  	preCEEd®	  	9/44	  	N/A	  	11/11/2005

2005-106514
	  	05/11/2007
 5046520

  
 13 

 Pending Registration: 

 

									
	 Outside Counsel
	  	Mark	  	Int’l
Class	  	Date Filed/
Serial #	  	 Status

	 US

	 Cooley Godward Kronish LLP
	  	FirstCEETM	  	1/9/44	  	3/19/2007

77/134,792 (IC 001)
 77/134793 (IC 009)
 77/134,796 (IC 044)
	  	 Allowed for all classes;
 SOU for Class 1&9 due 10/30/08;
 SOU for Class 44 due 1/1/09 (2nd ext.)

	 Cooley Godward Kronish LLP
	  	I.D. TM	  	1/5/44	  	05/15/2008
 77/475,119
	  	Awaiting Office Communication
	 Cooley Godward Kronish LLP
	  	preCEEdTM	  	1/9/44	  	06/10/2005

78/648,632 (IC 001/9)
	  	Allowed 7/24/07; Statement of Use due 1/24/09 (3rd ext.)
		  	  	  	07/17/200678/931,082
(IC 044)	  	Allowed 5/22/07; Statement of Use due 11/22/08 (3rd ext.)
	 European Community (CTM)

	 Cooley Godward Kronish LLP
	  	CEETM	  	9/42	  	11/17/2005
 4725545
	  	To be re-filed with more stylized format
	 Cooley Godward Kronish LLP
	  	FIRSTCEETM	  	1/5/9/44	  	09/17/2007
 6282719
	  	Replied to O.A. 11/25/07
	 Japan

	 Cooley Godward Kronish LLP
	  	CEETM	  	9/42	  	11/11/2005
 2005-106515
	  	Replied to O.A. 12/23/06
	 Cooley Godward Kronish LLP
	  	FIRSTCEETM	  	1/9/44	  	09/18/2007
 2007-098571
	  	Replied to Office Action 5/16/08 (all classes)

  
 14EX-10.17

 Exhibit 10.17 
 AMENDED AND RESTATED LOAN AGREEMENT 
 BETWEEN 
 GOODMAN CO.
LTD. 
 AND 
 BIOCEPT, INC. 
 WHEREAS, Biocept,
Inc., a California corporation (“Borrower”) and Goodman Co. Ltd. (“Lender”) are parties to that certain Amended and Restated Loan Agreement dated January 29, 2009 (the “Prior Loan Agreement”), which amended and
restated that certain Amended and Restated Loan Agreement dated June 26, 2007 (the “First Amended Loan Agreement”), which amended and restated that certain Loan Agreement dated April 20, 2005; 

WHEREAS, the Lender has agreed to amend the terms of the Prior Loan Agreement effective on the Effective Date (as defined below)
in order to extend the Maturity Date (as defined below), amend the timing of payments made by Borrower to Lender, and to provide for such other amendments as provided for herein; and 

WHEREAS, in order to document these amendments, Borrower and Lender desire to amend and restate in its entirety the Prior Loan
Agreement and to accept the rights and obligations created pursuant hereto in lieu of the rights and obligations granted them under the Prior Loan Agreement. 
 NOW THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, the parties to the Prior Loan Agreement hereby agree that the Prior Loan Agreement shall be superseded
and replaced in its entirety by this Amended and Restated Loan Agreement, and the parties hereto further agree as follows: 
 1.
Promise to Pay. Borrower hereby unconditionally promises to pay to the order of Lender in lawful money of the United States of America and in immediately available funds, the principal sum of Three Million Dollars ($3,000,000.00) (the
“Loan”), together with accrued and unpaid interest thereon, due and payable as set forth below. Once repaid, amounts under the Loan may not be reborrowed. 
 2. Funding. On April 20, 2005 (the “Closing Date”), Lender credited by wire transfer the full principal amount of the Loan at such time to Borrower’s account with such bank as
Borrower specified in writing to Lender. 
 3. Interest. 

(a) From the date of execution of the First Amended Loan Agreement through January 31, 2009, interest accrued in the
amount of and was paid in accordance with the First Amended Loan Agreement. 
 (b) From February 1, 2009
through April 30, 2010, interest began accruing on all amounts outstanding under the Loan at the rate of the variable rate of interest, per annum, published as the “prime lending rate” in the Wall Street Journal (the “Prior
Interest Obligation”). 

  
 1 

 The accrued Prior Interest Obligation was due and payable quarterly in arrears on the last
business day of each three-month quarter beginning February 1, 2009 through April 30, 2010 and was calculated on the basis of a 365 day year for the actual number of days elapsed. 

(c) On the Effective Date, Borrower shall pay Lender all unpaid interest which has accrued under the Loan pursuant to
Section 3(a) and 3(b) above. 
 (d) Following April 30, 2010, interest began accruing on all amounts
outstanding under the Loan at the fixed rate of 3.25% per annum (the “Revised Interest Obligation”). The accrued Revised Interest Obligation shall be due and payable quarterly in arrears on the last business day of each three-month
quarter beginning May 1, 2010 and shall be calculated on the basis of a 365 day year for the actual number of days elapsed. 
 4. Effective Date Balloon Payment. On the Effective Date, Borrower shall pay Lender $750,000, which such amount shall be credited towards the principal balance outstanding under the Loan, such that
immediately following the Effective Date, the principal sum of $2,250,000 shall be outstanding under the Loan. 
 5.
Quarterly Principal Payments. Beginning May 1, 2010, Borrower shall pay Lender the applicable Quarterly Principal Payment, which such amount shall be due and payable quarterly in advance on the first business day of each three-month
quarter beginning on May 1, 2010, which such amount shall be credited towards the principal balance outstanding under the Loan; provided, however, that the parties hereby agree that the Quarterly Principal Payment otherwise due and
payable on May 3, 2010 shall be paid to Lender on the Effective Date. The “Quarterly Principal Payment” shall be an amount equal to: 
 (a) for payments due and payable during the period between May 1, 2010 through December 31, 2011, the Quarterly Principal Payment shall be an amount equal to $45,000; 

(b) for payments due and payable during the period between January 1, 2012 through December 31, 2013, the
Quarterly Principal Payment shall be an amount equal to $90,000; and 
 (c) for payments due and payable during
the period between January 1, 2014 through the Maturity Date, the Quarterly Principal Payment shall be an amount equal to $150,000. 
 6. Maturity. On the earliest to occur of (a) the tenth anniversary of the Closing Date, (b) the date immediately prior to Borrower’s closing of an Acquisition or Asset Transfer (each
as defined in Borrower’s Amended and Restated Articles of Incorporation), or (c) the first business day following the closing of an equity financing transaction involving the sale by the Borrower of its equity securities, or securities
that are otherwise convertible into equity securities of the Borrower, in which the Borrower receives an aggregate of at least $25,000,000 in cumulative gross proceeds, any principal and interest amounts that remain outstanding under the Loan shall
be fully due and payable (the “Maturity Date”). 
 7. Prepayment. Borrower at any time may prepay any principal
amounts in whole or in part, together with the interest on the amount being prepaid up to the date of such payment, without penalty or premium. 
 8. Place of Payment. Unless another place of payment shall be specified in writing by Lender, all amounts payable hereunder shall be paid by wire transfer to Lender’s account with RESONA BANK,
LIMITED IMAIKE BRANCH as provided below: 

  
 2 

 RESONA BANK, LIMITED IMAIKE BRANCH 

5-1-5 IMAIKE, CHIKUSA-KU, NAGOYA, JAPAN 

Telegraphic Address: N/A 
 ABA Routing Number (SWIFT Address): DIWAJPT 
 Beneficiary Name:
GOODMAN CO., LTD. 

                    
            108 Fujigaoka, Meito-ku, Nagoya 465-0032 Japan 
 Account Number: 103571 
 Telephone: +81(52)774-4350 

9. Application of Payments. Except as otherwise provided for in Section 4 and Section 5, payments under this Amended and
Restated Loan Agreement shall be applied first to accrued interest, and thereafter to the outstanding principal balance hereof. 

10. Preferred Stock Warrant. In exchange for entering into the Prior Loan Agreement, Borrower issued Lender a Warrant to Purchase
Preferred Stock, exercisable for 1,000,000 shares of the Borrower’s Series AA Preferred Stock. 
 11. Security
Agreement. In exchange for entering into this Amended and Restated Loan Agreement, Borrower and Lender shall enter into a Subordinated Security Agreement, substantially in the form attached hereto as Exhibit A (the “Security
Agreement”), pursuant to which any principal and interest amounts that remain outstanding under the Loan shall be secured by a security interest in the assets of the Borrower as provided for in the Security Agreement. 

12. Binding Arbitration. Any dispute regarding this Amended and Restated Loan Agreement shall be resolved by binding arbitration.
Any such arbitration shall be conducted under the auspices of the International Arbitration Association and such proceedings shall be conducted under the Rules of Conciliation and Arbitration of the International Chamber of Commerce. 

13. Choice of Law. This Amended and Restated Loan Agreement shall be construed in accordance with the laws of the State of
California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.] 

  
 3 

 IN WITNESS WHEREOF, the parties hereto have caused this Amended and Restated Loan Agreement
to be executed on May 18, 2010 (the “Effective Date”). 
  

							
	 BORROWER
	 		 		 	 LENDER

				
	 BIOCEPT, INC.
	 		 		 	 GOODMAN CO. LTD.

				
	 By: /s/ S. M. Coutts
	 		 		 	 By: /s/ Takehito Yogo

				
	 Name: Stephen M. Coutts
	 		 		 	 Name: Takehito Yogo

				
	 Title: President & CEO
	 		 		 	 Title: President & CEO

 [SIGNATURE PAGE TO AMENDED AND
RESTATED LOAN AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]